William Aronson

Has grant

Chief of Urologic Oncology

VA Greater Los Angeles Healthcare System

United States

Research Interests

Explore related searches

Professors in United States Professors in Food Science Food Science professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

William Aronson is the Chief of Urologic Oncology at the VA West Los Angeles Medical Center in the United States. His research focuses on prostate cancer, with recent articles addressing issues such as racial disparities in pathology prediction models, the effects of dietary omega-3 fatty acids on cancer progression, and diabetes outcomes in men with nonmetastatic castration-resistant prostate cancer. Through his work, he contributes to advancing the understanding and treatment of prostate cancer in diverse populations.

Recent Grants

Grant: Close

Role of GPR120 and macrophages in dietary omega-3 fatty acid inhibition of prostate cancer

Open Date: 2018-09-01

Close Date: 2023-08-01

Articles (7)

Year:

2025

Year:

2025

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Collaborators (1)

Pinchas Cohen

Dean

University of Southern California

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

William Aronson

Research Interests

Explore related searches

Contact this professor

About

Recent Grants

Articles (7)

Addressing racial disparities in prostate cancer pathology prediction models: external validation and comparison of four models of pathological outcome prediction before radical prostatectomy in the multiethnic SEARCH cohort

High Omega-3, Low Omega-6 Diet With Fish Oil for Men With Prostate Cancer on Active Surveillance: The CAPFISH-3 Randomized Clinical Trial

Relative search popularity of five advanced prostate cancer medications using Google Trends

Effect of omega-3 fatty acid diet on prostate cancer progression and cholesterol efflux in tumor-associated macrophages—dependence on GPR120

Diabetes and Prostate Cancer Outcomes in Men with Nonmetastatic Castration-Resistant Prostate Cancer: Results from the SEARCH Cohort

Is time to castration resistant prostate cancer a potential intermediate end-point for time to metastasis among men initiating androgen deprivation therapy for non-metastatic prostate cancer with rapid PSA doubling time (<9 months)?

Effects of dietary omega-3 fatty acids on orthotopic prostate cancer progression, tumor associated macrophages, angiogenesis and T-cell activation—dependence on GPR120

Collaborators (1)

Pinchas Cohen

Make your next move.